Severe Acute Respiratory-Syndrome Treatment Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The severe acute respiratory-syndrome treatment market size has grown rapidly in recent years. It will grow from $3.45 billion in 2024 to $3.97 billion in 2025 at a compound annual growth rate (CAGR) of 15.2%. The growth in the historic period can be attributed to global outbreak response, antiviral drug development, vaccine development, public health preparedness.

The severe acute respiratory-syndrome treatment market size is expected to see rapid growth in the next few years. It will grow to $7.15 billion in 2029 at a compound annual growth rate (CAGR) of 15.8%. The growth in the forecast period can be attributed to broad-spectrum antivirals, emerging therapeutics, vaccine advancements, pandemic preparedness. Major trends in the forecast period include rna-targeted therapies, ai in drug discovery, global collaborations, public health education.

The increasing prevalence of respiratory diseases is expected to drive the growth of the severe acute respiratory syndrome (SARS) treatment market in the coming years. Respiratory diseases encompass a range of conditions that affect the respiratory system, which is responsible for breathing and facilitating gas exchange between the body and the environment. Treatments for severe acute respiratory syndrome aim to alleviate symptoms, prevent respiratory failure, reduce inflammation, and maintain oxygen levels. For example, in November 2023, the National Asthma Council, an Australia-based non-profit organization focused on asthma care, reported 467 asthma-related deaths in 2022, including 299 females and 168 males. This marked an increase from the 355 deaths recorded in 2021. Therefore, the rising incidence of respiratory diseases is fueling the growth of the severe acute respiratory syndrome treatment market.

The progressive surge in investments in research and development is poised to be a catalyst for the growth of the severe acute respiratory syndrome treatment market in the near future. These investments in research and development, often abbreviated as R&D, pertain to the allocation of financial resources and human expertise by organizations, governments, or entities with the aim of conducting systematic and innovative investigations and initiatives, with the goal of unearthing fresh knowledge. Augmented R&D investments play a pivotal role in advancing the array of available treatment options for severe acute respiratory syndromes, including conditions like SARS and COVID-19. Such investments contribute to the formulation of effective drugs, vaccines, diagnostic tools, and therapeutic strategies, ultimately enhancing patient outcomes and reinforcing global health preparedness. Notably, in August 2023, the United States Department of Health and Human Services, the executive branch department of the U.S. federal government, disclosed that the U.S. Department of Health and Human Services (HHS), in collaboration with the Administration for Strategic Preparedness and Response (ASPR), had allocated over $1.4 billion for Project NextGen. This initiative aims to support the development of the next generation of COVID-19 vaccines and treatments. Consequently, the increasing investments in research and development are the pivotal driving force behind the growth of the severe acute respiratory syndrome treatment market.

Leading companies actively participating in the severe acute respiratory syndrome treatment market are at the forefront of introducing innovative techniques, with a notable example being multiplexed real-time PCR. Multiplexed real-time PCR is a molecular biology technology that facilitates the simultaneous amplification and detection of multiple DNA or RNA targets in a single procedure. A case in point is the product launched by TransGen Biotech Co. Ltd., a Beijing-based manufacturer and researcher of molecular and cellular biology products, in July 2022. They introduced the Trans-SARS-CoV-2, Influenza A and B, and Respiratory Syncytial Virus Assay. This groundbreaking assay is designed as a multiplexed real-time PCR (polymerase chain reaction) assay, capable of detecting and distinguishing severe acute respiratory syndrome COVID-19 2 (SARS-CoV-2), Influenza A, Influenza B, and respiratory syncytial virus (RSV) in a single specimen. This innovative tool plays a crucial role in the diagnosis and treatment of severe acute respiratory syndromes, including COVID-19, influenza, and RSV, thus aiding in guiding treatment decisions and preventing the spread of these diseases.

In March 2022, AbbVie Inc., a U.S.-based pharmaceutical company, established a collaboration with Scripps Research, an independent, non-profit biomedical research and drug discovery institute also based in the United States. This strategic partnership is geared toward the development of cutting-edge direct-acting antiviral therapies designed for the treatment of COVID-19. The collaboration aims to pioneer innovative solutions for combatting the virus.

Major companies operating in the severe acute respiratory-syndrome treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck And Co Inc., Novartis AG, Bristol Myers Squib company, GlaxoSmithKline PLC, AstraZeneca PLC, Sanofi SA, Eli Lilly And Company, Gilead Sciences Inc., Amgen Inc., Johnson And Johnson Private Limited, Moderna Inc., Regeneron Pharmaceuticals Inc., Hetero labs Ltd., Alexion Pharmaceuticals Inc., Cadila healthcare Ltd., Genentech Inc., Cipla Ltd., Biogen Inc., Vir Biotechnology Inc., Swedish Orphan Biovitrum AB, Dynavax Technologies Corporation, ViiV Healthcare Limited, Panacea Biotec Limited, CureVac N.V., CN Bio Innovations Ltd., Inovio Pharmaceuticals Inc., Chimerix Inc.

North America was the largest region in the severe acute respiratory syndrome treatment market in 2024. Western Europe is expected to be the fastest-growing region in the forecast period. The regions covered in severe acute respiratory syndrome treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the severe acute respiratory syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The severe acute respiratory syndrome treatment market consists of revenues earned by entities by providing services such as respiratory therapy, oxygen therapy, ventilation, intensive care, isolation and infection control, fluid and electrolyte management and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The severe acute respiratory syndrome treatment market also includes sales of azithromycin, immunomodulators, vaccines, ribavirin, ritonavir, remdesivir, methylprednisolone, prednisolone, dexamethasone and interferon. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Severe acute respiratory syndrome (SARS) is a severe type of pneumonia caused by an airborne virus that can be transmitted through tiny droplets of saliva. This previously unidentified virus belongs to the Coronaviridae family and is known as SARS-associated COVID-19 (SARS-CoV). The treatment for severe acute respiratory syndrome (SARS) involves medical interventions and supportive measures aimed at managing the symptoms and complications of this viral respiratory illness.

The primary classes of drugs used in the treatment of severe acute respiratory syndrome include antibiotics, antivirals, corticosteroids, monoclonal antibodies, and others. Antibiotics are a class of medications used to treat bacterial infections. They function by either killing bacteria or inhibiting their growth, depending on the specific type of antibiotic. In the context of severe acute respiratory syndrome caused by SARS-CoV and SARS-CoV-2, these antibiotics are administered orally and intravenously. They are distributed through various channels, including hospital pharmacies and retail pharmacies, among others.

The severe acute respiratory syndrome treatment market research report is one of a series of new reports that provides severe acute respiratory-syndrome treatment market statistics, including severe acute respiratory-syndrome treatment industry global market size, regional shares, competitors with a severe acute respiratory syndrome treatment market share, detailed severe acute respiratory-syndrome treatment market segments, market trends and opportunities and any further data you may need to thrive in the severe acute respiratory-syndrome treatment industry. This severe acute respiratory-syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.